- gsearch

Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: About CDC.gov

Advanced Search

- gsearch

Search Results

Narrow Results:

2022 1

California 1

Journal Article 1

1 Results

Refine Results

All Collections

Refine Results:

All Collections

In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring

CITE Title : In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring Personal Author(s) : Murphy, Caitlin C.;Cirillo, Piera M.;Krigbaum, Nickilou Y.;Cohn, Barbara A.; Published Date : 1 2022 Source : Am J Obstet Gynecol. 226(1):132.e1-132.e14 URL : https://stacks.cdc.gov/view/cdc/113360 Murphy, Caitlin C. et al. (2022). In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring. 226(1). Murphy, Caitlin C. et al. "In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring" 226, no. 1 (2022) Murphy, Caitlin C. et al. "In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring" vol. 226, no. 1, 2022 Export RIS Citation Information.

:

Murphy, Caitlin C. ;

Cirillo, Piera M.

1 2022 | Am J Obstet Gynecol. 226(1):132.e1-132.e14

:

Background:17α-hydroxyprogesterone caproate (17-OHPC) is a synthetic progestogen initially approved in the 1950s to treat gynecological and obstetric...

To see more results, try removing search filters or changing the search terms